The American Journal of Managed Care

'Tis the Season: SABCS 2025 to Highlight Latest Advances Across the Breast Cancer Continuum

The symposium will present new research, including significant trials like HER2CLIMB-05, LidERA, and DESTINY-Breast11, through various sessions. SABCS 2025 will spotlight new advances in breast cancer ...

U.S. Recession Probability Drops Below 20%

The probability that NBER will someday determine a national recession began in the US between December 2025 and December 2026 ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive ...

AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or ...